Menopause associated with increased prevalence of cardiovascular autonomic neuropathy in women with diabetes: this study

Published Date: 02 Mar 2023

Spain: A recent study showed an increase in subclinical autonomic neuropathy (CAN) in women aged 1...

Read Full News

Latest News

Treat Aging, Not Diseases, to Extend Healthspan

Targeting aging rather than individual diseases could add more than a decade of healthy life, researchers say, citing centenarian studies and drug repurposing efforts.

Aardvark Pauses Late-stage Trial Testing Rare Disease Treatment

Aardvark Therapeutics is voluntarily pausing its late-stage trial testing its experimental treatment for a ⁠type of rare genetic disease after it found heart-related side...

FDA Okays New Indications for Once-Weekly Growth Hormone

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Daily Oral Option for Acromegaly Wins EU Backing

Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.

Patient-Centered Approaches in Obesity Case Management

Nonjudgmental and collaborative care plans are ideal for primary care clinicians treating patients with obesity.

Can OTC Remedies Help With GLP-1 Adherence?

GI side effects from GLP-1s may cause patients to drop the medications or turn to OTC remedies. Gastroenterologists don’t rule them out but also cite lack of evidence.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Latest News

Targeting aging rather than individual diseases could add more than a decade of healthy life, researchers say, citing centenarian studies and drug repurposing efforts.

Aardvark Therapeutics is voluntarily pausing its late-stage trial testing its experimental treatment for a ⁠type of rare genetic disease after it found heart-related side...

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.

Nonjudgmental and collaborative care plans are ideal for primary care clinicians treating patients with obesity.

GI side effects from GLP-1s may cause patients to drop the medications or turn to OTC remedies. Gastroenterologists don’t rule them out but also cite lack of evidence.

News All Time

Gut Flora May Be Altered by Oral Semaglutide Additive

Salcaprozate sodium, the absorption-enhancing ingredient used in oral semaglutide, is associated with changes in gut microbiota and inflammatory markers in a preclinical study.

ChatGPT Excels at Classifying Ultraprocessed Foods

ChatGPT accurately classifies foods by processing level and detects ultraprocessed items, which may help automate and improve future dietary research.

GPs ‘Reeling’ Over New Contract in England

A new GP contract for England promises same-day urgent appointments, but medical leaders warn it raises unrealistic expectations and workload risks.

Targeted Tablet Approved for ESR1 Breast Cancer

MHRA approval of imlunestrant offers a new option for patients with ESR1-mutated, ER-positive advanced breast cancer.

GLP-1 Drugs May Raise Fracture Risk in Older Adults With T2D

GLP-1 therapy is linked to an increased risk for fragility fractures among older adults with type 2 diabetes.

Healthy Lifestyle Lowers Cancer Survivor Mortality Risk

A large German cohort study finds that adherence to key lifestyle recommendations is associated with up to 32% lower mortality rate among long-term cancer survivors.

Hormone Therapy Myths Hinder Bone Health in Menopause

Experts warn that misinformation about menopausal hormone therapy may be increasing fracture risk in women.

Novo Nordisk, United Laboratories 'triple G' Drug Trial Shows 19.7% Weight Loss

Novo Nordisk and United Laboratories International said on Tuesday a Chinese mid-stage trial of their jointly developed "triple G" UBT251 obesity ⁠drug candidate resulted in...

CT-Based Approach Can Guide Pancreatic Stone Treatment

In patients with chronic pancreatitis, electrohydraulic lithotripsy performed via peroral pancreatoscopy can remove pancreatic duct stones, except for large or dense stones.

Can Remote Monitoring for Diabetes Reduce Hospitalizations?

Statistics routinely show remote monitoring works, but it takes a collaborative effort.

Most Americans With Obesity Perceive Just Having Overweight

Experiences of stigma and bias vary across ethnic and racial groups.

Quitting Smoking May Boost Prognosis in Graves Disease

Smoking intensity is linked to greater disease severity and the risk for relapse in patients with Graves disease in a dose-dependent manner.

SARS-CoV-2 Infection Linked to Higher Thyroid-Disease Risk

An analysis of medical records from a hospital system in the Bronx, New York, adds to findings linking SARS-CoV-2 infection to later diagnosis of thyroid conditions.

Novo Nordisk to Halve US List Price Of Wegovy From 2027

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year to $675 a ⁠month, the Danish...

Intermittent Fasting Offers No Clear Advantage

Analysis of 22 randomized trials finds intermittent fasting produces modest weight loss comparable to standard calorie-restricted diets and shows no clear quality-of-life benefit.

When Heavy or Light Periods Signal Reproductive Risk

Heavy or scant menses often reflect ovulatory, uterine, or hormonal disorders that can indirectly impair conception; targeted evaluation identifies treatable causes to protect fertility.

Recommended News For You

Bayer is transforming pharmaceutical research into women's health

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

More cancer cases in areas where incarceration rates are high: Study

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

Recommended Articles For You

Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis 

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment 

A Revolutionary Guide to Calculating Absolute Neutrophil Counts 

Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

2.

Bayer is transforming pharmaceutical research into women's health

3.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

4.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

5.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

1.

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities

2.

Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025

3.

Chondroma: What it is and How it Affects Your Health 

4.

Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer

5.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot